PTC Therapeutics, Inc. (NASDAQ:PTCT) is set to announce third quarter earning results on Thursday 29th October 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, PTCT to report 3Q20 loss of $ 0.06 per share.
For the full year, analysts anticipate top line of $ 367.87 million, while looking forward to loss of $ 5.52 per share bottom line.
Previous Quarter Performance
PTC Therapeutics, Inc. unfold loss for the second quarter of $ 2.62 per share, from the revenue of $ 75.24 million. Wall street analysts are predicting, PTCT to report 2Q20 loss of $ 1.30 per share from revenue of $ 82.78 million. The bottom line results missed street analysts by $ 1.32 or 101.54 percent, at the same time, top line results fell short of analysts by $ 7.54 million or 9.11 percent.
Stock Performance
Shares of PTC Therapeutics, Inc. traded low $ -0.79 or -1.48 percent on Wednesday, reaching $ 52.47 with volume of 435.10 thousand shares. PTC Therapeutics, Inc. has traded high as $ 53.04 and has cracked $ 50.77 on the downward trend
According to the previous trading day, closing price of $ 52.47, representing a 72.98 % increase from the 52 week low of $ 30.79 and a 11.07 % decrease over the 52 week high of $ 59.89.
The company has a market capital of $ 3.55 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 7th October 2020, upgraded by JPMorgan Chase & Co. to Overweight from Neutral rating.
Conference Call
PTC Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.ptcbio.com
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients.
